Sanofi (NASDAQ:SNY) Posts Earnings Results, Beats Expectations By $0.05 EPS

Sanofi (NASDAQ:SNY) posted its quarterly earnings results on Thursday. The company reported $0.93 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.88 by $0.05, Zacks reports. The business had revenue of $10.75 billion during the quarter, compared to analyst estimates of $16.86 billion. Sanofi had a return on equity of 38.98% and a net margin of 9.60%. The business’s revenue was up 7.8% compared to the same quarter last year. During the same period in the prior year, the business earned $0.95 earnings per share.

Sanofi Stock Performance

Shares of SNY traded down $0.70 during midday trading on Friday, reaching $52.40. 1,994,568 shares of the stock were exchanged, compared to its average volume of 2,357,098. The business’s 50-day moving average price is $49.21 and its 200 day moving average price is $48.69. The company has a debt-to-equity ratio of 0.19, a current ratio of 1.27 and a quick ratio of 0.87. Sanofi has a twelve month low of $42.63 and a twelve month high of $55.72. The company has a market capitalization of $132.72 billion, a price-to-earnings ratio of 26.33, a PEG ratio of 1.63 and a beta of 0.59.

Wall Street Analysts Forecast Growth

Several equities research analysts have issued reports on SNY shares. StockNews.com raised Sanofi from a “buy” rating to a “strong-buy” rating in a research note on Friday. Argus lifted their price objective on Sanofi from $55.00 to $60.00 and gave the company a “buy” rating in a research note on Friday. Three research analysts have rated the stock with a hold rating, two have issued a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, Sanofi has an average rating of “Moderate Buy” and an average price target of $57.50.

Sanofi Company Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.